Incyte Corp (NAS:INCY)
$ 57.05 -0.55 (-0.95%) Market Cap: 12.83 Bil Enterprise Value: 9.14 Bil PE Ratio: 17.29 PB Ratio: 2.38 GF Score: 88/100

Incyte Corp at Piper Jaffray Healthcare Conference Transcript

Dec 04, 2019 / 01:30PM GMT
Release Date Price: $95 (+0.96%)
Unidentified Analyst

Good morning, everyone. Thanks very much for being here and welcome to the second day of the 31st Annual Piper Jaffray Healthcare Conference. With us for this session, we're very pleased to have Incyte in attendance. And from Incyte, we have Hervé Hoppenot, the Chairman and President and CEO; and Christiana Stamoulis, the Executive Vice President and CFO.

Questions & Answers

Unidentified Analyst

So Hervé, as evidenced by the current stock price, you guys have had a pretty good year. And in addition to continuing to execute on the Jakafi Jakavi launch, and executing on the pipeline and the post IDO era, I thought it would be helpful just to start by discussing your confidence in the existing Jakavi Jakafi franchise and the breadth of the pipeline and the overall state of the business.

HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO

© -

Okay. Thank you. Thank you for having us here. So when you look at the portfolio of Incyte today, so you have the existing Jakafi franchise

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot